{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:00:58Z","timestamp":1794013258359,"version":"4.8.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.critrevonc.2025.104941","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:39:49Z","timestamp":1757781589000},"page":"104941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Immunotherapy in gastric adenocarcinoma \u2013 a rapidly evolving treatment landscape"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9365-3611","authenticated-orcid":false,"given":"Yang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10184","key":"10.1016\/j.critrevonc.2025.104941_bib1","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104941_bib2","author":"Al-Batran","year":"2022","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104941_bib3","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1007\/s12094-020-02380-0","article-title":"Prognostic impact of claudin 18.2 in gastric and esophageal adenocarcinomas","volume":"22","author":"Arnold","year":"2020","journal-title":"Clin. Transl. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104941_bib4","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.21873\/anticanres.13919","article-title":"Clinical implications of Claudin18. 2 expression in patients with gastric cancer","volume":"39","author":"Baek","year":"2019","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104941_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.canlet.2011.06.038","article-title":"Aberrant DNA methylation of cancer-associated genes in gastric cancer in the european prospective investigation into cancer and nutrition (EPIC\u2013EURGAST)","volume":"311","author":"Balassiano","year":"2011","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104941_bib6","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase III, randomised trial of avelumab versus physician\u2019s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN gastric 300","volume":"29","author":"Bang","year":"2018","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104941_bib7","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2217\/fon-2018-0581","article-title":"KEYNOTE-585: phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer","volume":"15","author":"Bang","year":"2019","journal-title":"Future Oncol."},{"issue":"9742","key":"10.1016\/j.critrevonc.2025.104941_bib8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104941_bib9","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/annonc\/mdx047","article-title":"Epstein\u2013Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations","volume":"28","author":"B\u00f6ger","year":"2017","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104941_bib10","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s10120-024-01535-0","volume":"27","author":"Boku","year":"2024","journal-title":"Gastric Cancer"},{"issue":"6545","key":"10.1016\/j.critrevonc.2025.104941_bib11","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.abg1209","article-title":"Bispecific antibodies","volume":"372","author":"Brinkmann","year":"2021","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104941_bib12","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1097\/PAI.0000000000000575","article-title":"Microsatellite instability: a predictive biomarker for cancer immunotherapy","volume":"26","author":"Chang","year":"2018","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104941_bib13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite Instability-High gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104941_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184659","article-title":"PD-L1 expression is significantly associated with tumor mutation burden and microsatellite instability score","volume":"13","author":"Cho","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104941_bib15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/SLA.0000000000002803","article-title":"\"Microsatellite instability and programmed cell death-ligand 1 expression in stage II\/III gastric cancer: post hoc analysis of the CLASSIC randomized controlled study","volume":"270","author":"Choi","year":"2019","journal-title":"Ann. Surg."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104941_bib16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes","volume":"21","author":"Cristescu","year":"2015","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104941_bib17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/gutjnl-2011-301839","article-title":"A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets","volume":"61","author":"Deng","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.critrevonc.2025.104941_bib18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00428-019-02624-7","article-title":"Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large caucasian cohort study","volume":"475","author":"Dottermusch","year":"2019","journal-title":"Virchows Arch."},{"key":"10.1016\/j.critrevonc.2025.104941_bib19","article-title":"Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors, American society","author":"Falchook","year":"2024","journal-title":"Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104941_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104941_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104941_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104941_bib23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa2409408","article-title":"Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer","volume":"392","author":"Hoeppner","year":"2025","journal-title":"New Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104941_bib24","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.21037\/tcr-19-1876","article-title":"Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer","volume":"9","author":"Hong","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104941_bib25","doi-asserted-by":"crossref","first-page":"S1315","DOI":"10.1016\/j.annonc.2023.10.074","article-title":"LBA73 pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC\/GEJC): interim results of the global, phase III MATTERHORN study","volume":"34","author":"Janjigian","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104941_bib26","doi-asserted-by":"crossref","first-page":"S877","DOI":"10.1016\/j.annonc.2024.08.1466","article-title":"1400O final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G\/GEJ adenocarcinoma","volume":"35","author":"Janjigian","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104941_bib27","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","author":"Janjigian","year":"2025","journal-title":"New Engl. J. Med."},{"issue":"10418","key":"10.1016\/j.critrevonc.2025.104941_bib28","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104941_bib29","doi-asserted-by":"crossref","unstructured":"Janjigian, Y.Y., D.-Y. Oh, M. Pelster, Z.A. Wainberg, E.A.R. Sison, J.R. Scott, J. Ronayne, D. Wishengrad, J. Rhee and D.S. Nuyten 2023. EDGE-Gastric Arm A1: Phase 2 study of domvanalimab, zimberelimab, and FOLFOX in first-line (1L) advanced gastroesophageal cancer, American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2023.41.36_suppl.433248"},{"issue":"10294","key":"10.1016\/j.critrevonc.2025.104941_bib30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104941_bib31","article-title":"Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma (GC\/GEJC\/EAC): 3-year follow-up from CheckMate 649, American society","author":"Janjigian","year":"2023","journal-title":"Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104941_bib32","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ijsu.2013.11.022","article-title":"Expression of claudin-7 and loss of claudin-18 correlate with poor prognosis in gastric cancer","volume":"12","author":"Jun","year":"2014","journal-title":"Int. J. Surg."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104941_bib33","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/ng.2984","article-title":"Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma","volume":"46","author":"Kakiuchi","year":"2014","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104941_bib34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104941_bib35","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S2468-1253(24)00156-0","volume":"9","author":"Kang","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104941_bib36","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2217\/fon-2018-0609","article-title":"KEYNOTE-590: phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer","volume":"15","author":"Kato","year":"2019","journal-title":"Future Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104941_bib37","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4251\/wjgo.v15.i2.343","article-title":"Prognostic value of claudin 18.2 expression in gastric adenocarcinoma","volume":"15","author":"Kayikcioglu","year":"2023","journal-title":"World J. Gastrointest. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104941_bib38","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s10120-024-01566-7","article-title":"Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression","volume":"28","author":"Kim","year":"2025","journal-title":"Gastric Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104941_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198347","article-title":"Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) t cells for the treatment of gastric cancer","volume":"13","author":"Kim","year":"2018","journal-title":"PlOS One"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104941_bib40","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104941_bib41","unstructured":"Klempner S.J., D F., Kratz J., et al. A phase 1b dose escalation study of givastomig, a CLDN18.2\u00d74-1BB bispecific antibody, in combination with immunochemotherapy in HER2-negative, CLDN18.2-positive gastric, esophageal or gastro-esophageal junction adenocarcinoma.\" Presented at: 2025 ESMO Gastrointestinal Cancers Annual Congress; July 2-5, 2025; Barcelona, Spain. Abstract 388MO."},{"key":"10.1016\/j.critrevonc.2025.104941_bib42","doi-asserted-by":"crossref","first-page":"S689","DOI":"10.1016\/j.annonc.2024.08.1076","article-title":"1017P updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2\/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)","volume":"35","author":"Klempner","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104941_bib43","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-24-4280","article-title":"A First-in-Human study of givastomig, a CLDN18.2 and 4-1BB bispecific antibody, as monotherapy in patients with CLDN18.2-Positive advanced or metastatic solid tumors","author":"Ku","year":"2025","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104941_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100762","article-title":"Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer","volume":"8","author":"Kubota","year":"2023","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104941_bib45","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","article-title":"Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer","volume":"143","author":"Kulangara","year":"2019","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104941_bib46","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4132\/jptm.2019.10.08","article-title":"Tumor immune response and immunotherapy in gastric cancer","volume":"54","author":"Kwak","year":"2020","journal-title":"J. Pathol. Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104941_bib47","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41467-022-35431-x","article-title":"Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104941_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35831","article-title":"Perioperative chemotherapy for gastric cancer patients with microsatellite instability or deficient mismatch repair: a systematic review and meta-analysis","volume":"131","author":"Liu","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104941_bib49","author":"Lordick","year":"2024","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104941_bib50","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104941_bib51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/PAI.0000000000000264","article-title":"Clinicopathologic characteristics of microsatellite instable gastric carcinomas revisited: urgent need for standardization","volume":"25","author":"Mathiak","year":"2017","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"7378","key":"10.1016\/j.critrevonc.2025.104941_bib52","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104941_bib53","doi-asserted-by":"crossref","unstructured":"Moehler, M.H., M. Dvorkin, M. Ozguroglu, M.-h Ryu, A.S. Muntean, S. Lonardi, M. Nechaeva, A.S. Campos Bragagnoli, H.S. Coskun and A. Cubillo Graci\u00e1n 2020. Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2\u2212 advanced gastric or gastroesophageal junction cancer (GC\/GEJC), American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2020.38.4_suppl.278"},{"key":"10.1016\/j.critrevonc.2025.104941_bib54","doi-asserted-by":"crossref","unstructured":"Moehler, M.H., K. Kato, H.-T. Arkenau, D.-Y. Oh, J. Tabernero, M. Cruz-Correa, H. Wang, H. Xu, J. Li and S. Yang 2023. Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC\/GEJC), American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2023.41.4_suppl.286"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104941_bib55","first-page":"3665","article-title":"Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies","volume":"19","author":"Moentenich","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2025.104941_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101404","article-title":"The current and future incidence and mortality of gastric cancer in 185 countries, 2020\u201340: a population-based modelling study","volume":"47","author":"Morgan","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104941_bib57","doi-asserted-by":"crossref","first-page":"9603","DOI":"10.1158\/0008-5472.CAN-05-2782","article-title":"Claudin proteins in human cancer: promising new targets for diagnosis and therapy","volume":"65","author":"Morin","year":"2005","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104941_bib58","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"issue":"7517","key":"10.1016\/j.critrevonc.2025.104941_bib59","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Network","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104941_bib60","first-page":"1","article-title":"Adjuvant chemotherapy for gastric cancer patients with mismatch repair deficiency or microsatellite instability: systematic review and meta-analysis","author":"Nie","year":"2021","journal-title":"Ann. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104941_bib61","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"35","key":"10.1016\/j.critrevonc.2025.104941_bib62","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.19.01124","article-title":"Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104941_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100036","article-title":"Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials","volume":"6","author":"Pietrantonio","year":"2021","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104941_bib64","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/1078-0432.CCR-24-1552","article-title":"A First-in-Human study of cinrebafusp alfa, a HER2\/4-1BB bispecific molecule, in patients with HER2-Positive advanced solid malignancies","volume":"31","author":"Piha-Paul","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104941_bib65","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18. 2-specific CAR t cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104941_bib66","article-title":"Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer, American society","author":"Rha","year":"2023","journal-title":"Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104941_bib67","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104941_bib68","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/jjco\/hyz068","article-title":"Comparison of claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma","volume":"49","author":"Rohde","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104941_bib69","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104941_bib70","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/modpathol.2016.202","article-title":"Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein\u2013Barr virus-associated gastric cancer: the prognostic implications","volume":"30","author":"Saito","year":"2017","journal-title":"Mod. Pathol."},{"issue":"33","key":"10.1016\/j.critrevonc.2025.104941_bib71","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","article-title":"Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer","volume":"29","author":"Sasako","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104941_bib72","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18. 2-Positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104941_bib73","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41591-024-03450-4","article-title":"First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial","volume":"31","author":"Shen","year":"2025","journal-title":"Nat. Med."},{"issue":"7903","key":"10.1016\/j.critrevonc.2025.104941_bib74","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.critrevonc.2025.104941_bib75","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-Positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"10389","key":"10.1016\/j.critrevonc.2025.104941_bib76","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18. 2-Positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"10142","key":"10.1016\/j.critrevonc.2025.104941_bib77","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104941_bib78","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol."},{"issue":"10251","key":"10.1016\/j.critrevonc.2025.104941_bib79","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104941_bib80","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","article-title":"Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (MAGIC) trial","volume":"3","author":"Smyth","year":"2017","journal-title":"JAMA Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104941_bib81","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1158\/1078-0432.CCR-16-2211","article-title":"Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome Atlas project","volume":"23","author":"Sohn","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104941_bib82","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s13238-017-0384-8","article-title":"Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo","volume":"9","author":"Song","year":"2018","journal-title":"Protein Cell"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104941_bib83","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104941_bib84","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12935-022-02471-8","article-title":"Antitumor responses in gastric cancer by targeting B7H3 via chimeric antigen receptor t cells","volume":"22","author":"Sun","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104941_bib85","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA a Cancer J. Clin."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104941_bib86","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.2217\/fon-2021-0176","article-title":"KEYNOTE-859: a phase III study of pembrolizumab plus chemotherapy in gastric\/gastroesophageal junction adenocarcinoma","volume":"17","author":"Tabernero","year":"2021","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104941_bib87","first-page":"39","article-title":"Upregulation of immune checkpoint molecules, PD-1 and LAG-3, on CD4+ and CD8+ t cells after gastric cancer surgery","volume":"58","author":"Takaya","year":"2015","journal-title":"Yonago Acta Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104941_bib88","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1749-6632.2000.tb05235.x","article-title":"The structure and function of claudins, cell adhesion molecules at tight junctions","volume":"915","author":"Tsukita","year":"2000","journal-title":"Ann. New Y. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2025.104941_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.643872","article-title":"Clinicopathologic relevance of claudin 18.2 expression in gastric cancer: a meta-analysis","volume":"11","author":"Ungureanu","year":"2021","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104941_bib90","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1200\/JCO.2004.08.061","article-title":"EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement","volume":"22","author":"van Beek","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104941_bib91","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","article-title":"HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer","volume":"18","author":"Van Cutsem","year":"2015","journal-title":"Gastric Cancer"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104941_bib92","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1200\/JCO.2011.39.9824","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"44","key":"10.1016\/j.critrevonc.2025.104941_bib93","doi-asserted-by":"crossref","first-page":"16433","DOI":"10.3748\/wjg.v20.i44.16433","article-title":"Causes and consequences of microsatellite instability in gastric carcinogenesis","volume":"20","author":"Velho","year":"2014","journal-title":"World J. Gastroenterol. WJG"},{"key":"10.1016\/j.critrevonc.2025.104941_bib94","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ctrv.2018.04.002","article-title":"Bispecific antibodies in haematological malignancies","volume":"65","author":"Viardot","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104941_bib95","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1158\/1078-0432.CCR-20-2980","article-title":"Efficacy of pembrolizumab monotherapy for advanced gastric\/gastroesophageal junction cancer with programmed death ligand 1 combined positive score\u2265 10","volume":"27","author":"Wainberg","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104941_bib96","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104941_bib97","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.celrep.2015.06.020","article-title":"Recurrent fusion genes in gastric cancer: CLDN18-ARHGAP26 induces loss of epithelial integrity","volume":"12","author":"Yao","year":"2015","journal-title":"Cell Rep."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104941_bib98","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jamaoncol.2022.3707","article-title":"Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 phase 3 randomized clinical trials","volume":"8","author":"Yoon","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.104941_bib99","doi-asserted-by":"crossref","unstructured":"Zheng, Z., Z. Wang, S. Cheng, Y. Zhou, W. Liao, B. Zhen and Y. Chen 2023. Genomic characterization of MSI-H and TMB in gastrointestinal cancer, American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2023.41.16_suppl.e15524"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:15:20Z","timestamp":1767388520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":99,"alternative-id":["S1040842825003294"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104941","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in gastric adenocarcinoma \u2013 a rapidly evolving treatment landscape","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104941","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104941"}}